In NSCLC, pemetrexed, a multi-targeted chemotherapeutic agent interfering with folate metabolic processes, strengthened the expression of HLA-G and PD-L1 by promoting glycosylation. The gene discussed is CD274; the disease is non-small cell lung carcinoma.